KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ginkgo Bioworks Holdings (DNA) Change in Account Payables (2020 - 2023)

Ginkgo Bioworks Holdings (DNA) has disclosed Change in Account Payables for 4 consecutive years, with -$6.7 million as the latest value for Q2 2023.

  • For the quarter ending Q2 2023, Change in Account Payables rose 57.14% year-over-year to -$6.7 million, compared with a TTM value of -$18.5 million through Jun 2023, down 217.66%, and an annual FY2025 reading of -$3.0 million, down 162.71% over the prior year.
  • Change in Account Payables was -$6.7 million for Q2 2023 at Ginkgo Bioworks Holdings, down from $9.7 million in the prior quarter.
  • Across five years, Change in Account Payables topped out at $26.2 million in Q1 2022 and bottomed at -$15.6 million in Q2 2022.
  • Average Change in Account Payables over 4 years is -$525363.6, with a median of $516000.0 recorded in 2021.
  • Peak annual rise in Change in Account Payables hit 4987.21% in 2022, while the deepest fall reached 2912.4% in 2022.
  • Year by year, Change in Account Payables stood at $4.3 million in 2020, then tumbled by 87.87% to $524000.0 in 2021, then crashed by 2912.4% to -$14.7 million in 2022, then surged by 54.63% to -$6.7 million in 2023.
  • Business Quant data shows Change in Account Payables for DNA at -$6.7 million in Q2 2023, $9.7 million in Q1 2023, and -$14.7 million in Q4 2022.